{"classes":[{"categories":[{"measurements":[{"comment":"Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"29.3","upperLimit":"NA","value":"57.7"},{"comment":"Not reached due to insufficient number of events","groupId":"OG001","lowerLimit":"58.3","upperLimit":"NA","value":"NA"},{"comment":"Not reached due to insufficient number of events","groupId":"OG002","lowerLimit":"29.5","upperLimit":"NA","value":"48.4"},{"comment":"Not reached due to insufficient number of events","groupId":"OG003","lowerLimit":"28.6","upperLimit":"NA","value":"NA"},{"comment":"Not reached due to insufficient number of events","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"165"}],"units":"Participants"}],"description":"OS was measured from start of treatment until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG000","title":"Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG001","title":"Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG002","title":"Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W"},{"description":"Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).","id":"OG003","title":"Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W"},{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG004","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"MEDIAN","populationDescription":"The FAS included all enrolled participants. Here, 'Overall number of participants analyzed' signifies participants who received at least one dose of cemiplimab and were evaluable for this outcome measure. Only Groups 1, 2, 3, 4, and 6 were planned for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 65 months (treatment period + follow-up including survival follow-up)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}